Evidence map›Paper›PMID 30093945›Full record

ArticleAmerican journal of translational research2018

Celastrol aggravates LPS-induced inflammation and injuries of liver and kidney in mice.

Mengqiu Wu, Weiyi Chen, Xiaowen Yu, Dan Ding, Wen Zhang, Hu Hua, Man Xu, Xia Meng, Xuejuan Zhang, Yue Zhang and 3 more

Open access · greenAbstract read
In one paragraph

Article in American journal of translational research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
6.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 52 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Recent Trends in anti-tumor mechanisms and molecular targets of celastrol.International journal of biological sciences · 2024
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Mengqiu WuDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Weiyi ChenDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Xiaowen YuDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Dan DingDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Wen ZhangDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Hu HuaDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Man XuDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Xia MengDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Xuejuan ZhangDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Yue ZhangDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Aihua ZhangDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Zhanjun JiaDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Songming HuangDepartment of Nephrology, Children's Hospital of Nanjing Medical University 72 Guangzhou Road, Nanjing 210008, P. R. of China.
Nanjing Children's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis, a life-threatening syndrome with uncontrolled inflammatory response, causes high morbidity and mortality worldwide. Currently, satisfactory treatments on sepsis are still lacking in clinic. Thus, new therapeutic strategies are urgently required. Recently, celastrol, a pentacyclic triterpene extracted from the traditional Chinese medicine Tripterygium Wilfordi plant, attracted great interest for its properties of anti-inflammation, anti-oxidative stress, and metabolism remodeling. However, the effect of celastrol on sepsis is still unclear. In this study, we investigated the effect of celastrol on lipopolysaccharides (LPS)-induced inflammation and organ injuries in mice. Following celastrol pretreatment, mice showed increased mortality rate and aggravated inflammation evidenced by further enhanced inflammatory markers of IL-6, IL-1β, TNF-α, IL-18, MCP-1, and ICAM-1 in circulation, liver, and kidney after LPS treatment. The serum levels of ALT, AST, and LDH were further increased in parallel with the deteriorated liver morphological damage (H&E) and oxidative stress in celastrol-treated mice, indicating an aggravated liver injury. In kidney, the expressions of tubular injury markers of kidney injury molecule-1 (KIM-1) and gelatinase-associated lipocalin (NGAL) were further upregulated along with higher levels of blood urea nitrogen (BUN), creatinine (Cr), and MDA in celastrol-treated mice. These findings not only indicated a detrimental role of celastrol therapy in LPS-induced inflammation and organ injuries but also suggested the restriction of celastrol usage in sepsis patients.

Indexed as

celastrolinflammationkidney injuryliver injuryLPS

Identifiers

PMID30093945
PMCPMC6079122
OpenAlexW2981629478

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.